20.77
前日終値:
$20.43
開ける:
$20.62
24時間の取引高:
127.60K
Relative Volume:
0.38
時価総額:
$1.05B
収益:
当期純損益:
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
City Therapeutics, Inc. Common Stock Stock (CTY) Company Profile
Compare CTY vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
CTY
City Therapeutics, Inc. Common Stock
|
20.77 | 1.05B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
|
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
City Therapeutics, Inc. Common Stock (CTY) 最新ニュース
City Therapeutics Director Ron M Philip Awarded 22,649-Share Stock Option - Kalkine Media
ARCH Venture Fund XII Converts Preferred Shares to Common Stock at City Therapeutics IPO - Kalkine Media
City Therapeutics closes $230 million upsized IPO By Investing.com - Investing.com South Africa
At its IPO close, City Therapeutics (CTY) saw ARCH buy 170,000 shares and convert preferred stock. - Stock Titan
At the IPO closing, ARCH bought 170,000 City Therapeutics (CTY) shares at $18 each. - Stock Titan
IPO conversion gives City Therapeutics (CTY) director John Maraganore 610,759 common shares. - Stock Titan
Director receives 22,649 stock options with an $18 exercise price at City Therapeutics (CTY). - Stock Titan
IPO closing fully vests 77,979 CEO options at City Therapeutics (CTY). - Stock Titan
A director receives 22,649 City Therapeutics (CTY) options with an $18 exercise price. - Stock Titan
Barry E. Greene acquires an option on 22,649 City Therapeutics (CTY) shares with an $18 exercise price. - Stock Titan
City Therapeutics closes $230 million upsized IPO By Investing.com - Investing.com Canada
A company developing medicines that silence genes brought in about $230 million before costs. - Stock Titan
City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Yahoo Finance Singapore
City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - GlobeNewswire
City Therapeutics, Inc. (CTY) Company Information - Simply Wall Street
City Therapeutics (CTY) director Barry E. Greene holds an option to buy 59,878 shares at $0.92 each. - Stock Titan
A director’s City Therapeutics (CTY) holdings include an option for 135,611 shares at $5.36. - Stock Titan
Director Ron M. Philip holds a $0.92 option on 59,878 City Therapeutics (CTY) shares - Stock Titan
Medical chief holds options with $1.84 and $5.36 exercise prices at City Therapeutics (CTY). - Stock Titan
CEO holds 1.06M shares in City Therapeutics (CTY), plus options priced at $0.92 and $5.36. - Stock Titan
Holdings in City Therapeutics (CTY) include 2.72M common shares and convertible preferred stock. - Stock Titan
Director Sara Nochur holds an option on 59,878 City Therapeutics (CTY) shares at a $0.92 exercise price. - Stock Titan
City Therapeutics prices IPO at $18 per share, raising $200M - Investing.com
A stock sale is expected to bring City Therapeutics about $200 million. - Stock Titan
City Therapeutics (CTY) COO holds 534,511 shares plus options exercisable at $0.92 and $5.36. - Stock Titan
City Therapeutics, Inc. Common Stock (CTY) 財務データ
City Therapeutics, Inc. Common Stock (CTY) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
City Therapeutics, Inc. Common Stock (CTY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Oct 19 '26 |
Buy |
18.00 |
170,000 |
3,060,000 |
13,692,507 |
大文字化:
|
ボリューム (24 時間):